Clinical Interpretation

Diagnosis: Acute Decompensated Ischemic Cardiomyopathy / NSTEMI with Severely Reduced EF

Assessment of Current Management

✅ Appropriate Drugs

⚠️ Issues and Concerns

1. Telmisartan — Potentially Problematic Right Now

• An ARB (telmisartan) is appropriate for chronic HFrEF if ACE-I is not tolerated.
• However, in acute decompensated heart failure (ADHF) with EF 25%, initiating or continuing an ARB/ACE-I in the acute phase carries risk of hypotension and worsening renal perfusion.
• Preferred: Stabilise first (diurese, decongest), then initiate/optimise neurohormonal therapy.
• If already on telmisartan, it may be continued cautiously but dose should be reviewed.
• Sacubitril/valsartan (ARNI) is now the preferred agent over ARBs in HFrEF — consider transition once stabilised.

2. Beta-Blocker is Missing

• Beta-blockers (carvedilol, bisoprolol, metoprolol succinate) are foundational therapy for HFrEF — MERIT-HF, COPERNICUS, CIBIS-II all show mortality benefit.
• In acute decompensation: do NOT initiate a new beta-blocker if the patient is fluid overloaded or haemodynamically compromised.
• If previously on beta-blocker: do not abruptly stop — reduce dose rather than discontinue.
• Plan to initiate at low dose once euvolaemia is achieved.

3. UFH Dosing — Inadequate for ACS

• 5000 IU IV QID = 20,000 IU/day = prophylactic dosing.
• For NSTEMI therapeutic anticoagulation: use weight-based IV heparin infusion protocol or enoxaparin 1 mg/kg SC BD.
• If the intent is bridge anticoagulation for mural thrombus risk (EF 25% → high LV thrombus risk), the dosing is still subtherapeutic.

4. No P2Y12 Inhibitor / DAPT

• Ecospirin alone is insufficient for NSTEMI.
• Add clopidogrel 300 mg loading, then 75 mg OD OR ticagrelor 180 mg loading, then 90 mg BD.
• Caution: balance bleeding risk if INR elevated from congestive hepatopathy.

5. Statin is Missing

• High-intensity statin (atorvastatin 40–80 mg) is mandatory in all ACS/ischaemic heart disease.

6. Coronary Angiography — Urgent Consideration

• RWMAs + extensive anterior ST-T changes + EF 25% strongly suggests a culprit coronary lesion (likely LAD).
• This patient likely needs invasive coronary angiography ± PCI once haemodynamically stabilised.
• Early revascularisation in NSTEMI with high-risk features (Killip class III/IV, EF <40%) improves outcomes.

7. Congestive Hepatopathy / Coagulopathy Risk

• Bilirubin 5, indirect-predominant: consistent with hepatic venous congestion.
• Check: PT/INR, LFTs (AST/ALT), albumin — hepatic synthetic function may be impaired.
• This affects drug metabolism (warfarin caution if needed later, dose adjustments).
• Aggressive decongestion with torsemide + aldactone should help improve hepatic congestion.

8. Monitor for Cardiorenal Syndrome

• EF 25% + diuretic therapy + potential renal hypoperfusion → watch creatinine, urea, electrolytes closely.
• Hypokalaemia risk with torsemide; aldactone provides potassium-sparing counterbalance — check serum K⁺ regularly.

Optimised Management Summary

Immediate

• Therapeutic anticoagulation: Weight-based IV UFH infusion (or enoxaparin 1 mg/kg BD, adjusted for renal function) — not fixed-dose prophylactic heparin
• Add P2Y12 inhibitor: Clopidogrel 75 mg OD (or ticagrelor if no bleeding risk)
• Add high-intensity statin: Atorvastatin 40–80 mg OD
• Urgent coronary angiography: Plan for early invasive strategy given high-risk NSTEMI features

Decongestion

• Continue torsemide — titrate to achieve adequate diuresis (target 0.5–1 mL/kg/hr urine output)
• Continue spironolactone — useful for ascites and HFrEF

Neurohormonal / HFrEF

• Telmisartan: continue at lowest tolerable dose, or switch to sacubitril/valsartan once stable (PARADIGM-HF)
• Dapagliflozin: continue — evidence-based for HFrEF
• Beta-blocker: defer initiation until decongested and haemodynamically stable, then start carvedilol 3.125 mg BD

Anti-ischaemic

• Trimetazidine + ranolazine: reasonable adjuncts
• Consider IV nitrates if blood pressure allows (for symptom relief and preload reduction)

Monitoring

• Daily: weight, fluid balance, electrolytes (K⁺, Na⁺), creatinine, urea
• Repeat LFTs in 48–72 hrs
• aPTT if on IV UFH infusion
• Serial ECGs and troponin

One Critical Gap

Beta-Blocker — Correct to Hold

• Do NOT initiate a new beta-blocker in acute decompensated HF with fluid overload (oedema, ascites, congestion)
• Reason: negative inotropy can worsen low-output state; patient needs to be euvolaemic first
• Plan: once decongested with torsemide + aldactone over several days, start carvedilol 3.125 mg BD at lowest dose
• Carvedilol is preferred in ischaemic cardiomyopathy — combined α1 + β1/β2 blockade, also reduces afterload

Telmisartan 40 mg — Reasonable, but One Concern

• Rationale for starting ARB early: neurohormonal blockade limits further remodelling — valid
• Risk: in EF 25% with renal hypoperfusion, ARBs can precipitate acute cardiorenal syndrome (creatinine rise, hypotension)
• Potassium caveat: you already have aldactone on board — once K⁺ returns, if it is ≥4.5 mEq/L, telmisartan should be held or used at lowest dose with close monitoring
• If K⁺ is normal/low, telmisartan 40 mg is reasonable to continue
• Long-term: once stable, consider switching to sacubitril/valsartan (ARNI) — superior to ARBs alone in HFrEF (PARADIGM-HF), but do not initiate in acute phase

Subtherapeutic Heparin + Aspirin Only — Justified Holding Pattern

Once Results Return:

• Upgrade heparin: weight-based IV UFH infusion (60 U/kg bolus, 12 U/kg/hr, titrate to aPTT 60–80 sec) OR enoxaparin 1 mg/kg SC BD
• Add clopidogrel 300 mg loading → 75 mg OD (if INR not markedly elevated, no active bleeding)
• Plan coronary angiography

• Be cautious with LMWH — prefer IV UFH (reversible, titratable)
• Clopidogrel can still be added but weigh bleeding risk carefully
• The elevated bilirubin (indirect-predominant) already signals hepatic congestion → synthetic function may be mildly impaired

• Reconsider diagnosis — could be demand ischaemia (Type 2 MI) or severe non-ischaemic CMP
• Repeat troponin at 3–6 hours (serial sampling mandatory)
• ECG pattern still warrants urgent cardiology review regardless

One Addition to Consider Now (While Awaiting Results)

Summary of Your Stepwise Approach

Troponin Negative — What Does This Mean Here?

Mandatory: Serial Troponin

Revised Differential Diagnosis

1. Established Ischaemic Cardiomyopathy (Old MI, Not Acute)

• Most likely explanation
• RWMAs reflect old healed infarcts (fibrosis/scar), not acute necrosis
• ST-T inversions represent chronic ischaemic pattern / LV strain on a background of severe LV dysfunction
• Troponin negative because there is no fresh myonecrosis right now
• The presentation (dyspnoea, oedema, ascites) is acute decompensation of chronic ischaemic CMP
• Ask: any prior MI? Prior angiography? Old ECGs for comparison?

2. Dilated Cardiomyopathy (Non-Ischaemic)

• Can have RWMAs (not always global)
• ST-T changes from LV strain
• But the ST-T pattern V1–V6 + I + aVL is more suggestive of ischaemic territory

3. Wellens' Syndrome — Early Presentation

• Troponin may be negative or minimally elevated at presentation (Wellens' often presents in pain-free window)
• The T-wave inversions represent reperfusion pattern after transient LAD occlusion
• Troponin may rise on serial testing
• Critically: Wellens' is a pre-infarction pattern — these patients are at high risk of sudden anterior STEMI
• Exercise stress testing is absolutely contraindicated in Wellens'

4. Takotsubo Cardiomyopathy

• Apical ballooning, RWMAs, diffuse ST-T changes, negative or mildly positive troponin
• Typically post-emotional/physical stress in older women — less likely here but consider

Implications for Management — Revised

Anticoagulation (UFH)

• With negative troponin + normal coags, the rationale for therapeutic anticoagulation (for NSTEMI) is not yet established
• However: EF 25% with severely impaired LV function is an independent risk for LV mural thrombus formation
• Recommendation: Therapeutic anticoagulation is still warranted — not for NSTEMI, but for LV thrombus prophylaxis
  • EF <35% with anterior wall motion abnormality → high thrombus risk
  • Use warfarin (target INR 2–3) or rivaroxaban 15–20 mg OD for 3–6 months if LV thrombus is present/suspected
  • Upgrade heparin to therapeutic dosing while planning further workup
  • Do apical echo views specifically to look for LV thrombus

Aspirin

• Continue ecospirin 150 mg
• Hold clopidogrel for now — DAPT is indicated for confirmed ACS; with negative troponin, you can defer the second antiplatelet until serial troponins are complete and diagnosis is clearer

Statin

• Start atorvastatin 40–80 mg now — regardless of troponin result, the ECG + RWMAs + clinical picture all point to atherosclerotic disease

Further Workup Now Essential

Revised Management Plan

Bottom Line

1. Serial troponins — 3h and 6h
2. Dedicated echo for LV thrombus
3. Therapeutic anticoagulation regardless (LV thrombus risk)
4. Coronary angiography — urgent, not emergent (timing based on serial troponin results)

Potassium 4.8 mEq/L — High-Normal, Concerning

Immediate Actions

Target

• Keep K⁺ between 4.0–4.5 mEq/L in HF (reduces arrhythmia risk)
• Recheck electrolytes in 12–24 hours before re-introducing aldactone or telmisartan
• When K⁺ comes down to ≤4.5: can restart aldactone at lowest dose (25 mg OD) and then cautiously reintroduce telmisartan
• Do not run both ARB + aldactone together until K⁺ is stable and renal function is confirmed

Sodium 132 mEq/L — Hyponatraemia, Significant

This is Dilutional / Hypervolaemic Hyponatraemia in this context

• EF 25% → low cardiac output → non-osmotic ADH release (baroreceptor-mediated)
• ADH causes free water retention → dilutional hyponatraemia
• Also: excess aldosterone activity, poor renal perfusion

Why This Matters

Management of Hyponatraemia Here

• Do NOT correct rapidly — target rise of no more than 6–8 mEq/L per 24 hours
• Fluid restriction: restrict free water to 800–1000 mL/day — this is the most important intervention
• Continue torsemide — decongestion will help correct the dilutional component
• Avoid: hypotonic fluids, excessive oral water intake
• Dapagliflozin: SGLT2 inhibitors cause mild osmotic diuresis (glucose + water loss) — may modestly help hyponatraemia, another reason to continue it
• Do NOT use hypertonic saline — this is dilutional, not depletional hyponatraemia
• Recheck sodium in 12–24 hours

Telmisartan and Hyponatraemia

• ARBs can worsen hyponatraemia in HF by promoting further neurohormonal activation and fluid retention in some patients
• Combined with K⁺ of 4.8 — another reason to hold telmisartan for now
• Reintroduce once sodium and potassium have stabilised

Revised Drug Chart with These Results

Monitoring Plan — Next 24 Hours

• Electrolytes (K⁺, Na⁺, Cl⁻) at 12h and 24h
• Renal function (creatinine, urea) — aggressive diuresis + hypoperfusion risk
• Fluid balance chart — strict input/output
• Fluid restriction 800–1000 mL/day
• Daily weight
• Serial troponin at 3h and 6h from presentation (still pending)
• Dedicated echo for LV thrombus